Rxsight Ebitda from 2010 to 2024

RXST Stock  USD 46.38  1.55  3.46%   
Rxsight EBITDA yearly trend continues to be comparatively stable with very little volatility. EBITDA will likely drop to about -43.1 M in 2024. From the period from 2010 to 2024, Rxsight EBITDA quarterly data regression had r-value of  0.09 and coefficient of variation of (53.13). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-41 M
Current Value
-43.1 M
Quarterly Volatility
19.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rxsight financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rxsight's main balance sheet or income statement drivers, such as Tax Provision of 18.9 K, Net Interest Income of 3.4 M or Interest Income of 6.9 M, as well as many indicators such as Price To Sales Ratio of 14.82, Dividend Yield of 0.0 or PTB Ratio of 9.1. Rxsight financial statements analysis is a perfect complement when working with Rxsight Valuation or Volatility modules.
  
Check out the analysis of Rxsight Correlation against competitors.
For more information on how to buy Rxsight Stock please use our How to Invest in Rxsight guide.

Latest Rxsight's Ebitda Growth Pattern

Below is the plot of the Ebitda of Rxsight over the last few years. It is Rxsight's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rxsight's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Very volatile
   Ebitda   
       Timeline  

Rxsight Ebitda Regression Statistics

Arithmetic Mean(36,953,390)
Geometric Mean40,978,251
Coefficient Of Variation(53.13)
Mean Deviation9,214,319
Median(40,354,000)
Standard Deviation19,632,252
Sample Variance385.4T
Range89.9M
R-Value0.09
Mean Square Error412.1T
R-Squared0.01
Significance0.76
Slope373,332
Total Sum of Squares5396T

Rxsight Ebitda History

2024-43.1 M
2023-41 M
2022-57.8 M
2021-41 M
202032.2 M

About Rxsight Financial Statements

Rxsight shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Rxsight investors may analyze each financial statement separately, they are all interrelated. The changes in Rxsight's assets and liabilities, for example, are also reflected in the revenues and expenses on on Rxsight's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-41 M-43.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Rxsight Stock Analysis

When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.